Arthur E. Brown is co-chair of Kaye Scholer’s Product Liability Group, and a member of the firm’s Complex Commercial Litigation Group. His practice focuses on representing and advising clients on mass tort and product liability issues, investigations by federal and state authorities, inquiries from Congress and commercial litigation disputes. As part of his practice, Arthur frequently serves as national counsel representing pharmaceutical companies in mass tort product liability actions, advises clients on strategic litigation and settlement decisions in the areas of commercial litigation and white collar investigations, and counsels clients on litigation avoidance.
Arthur currently represents Novartis in product liability claims alleging its blood pressure medication, Tekturna, causes kidney and other injuries; he also represents Pfizer in asbestos litigation. Arthur recently served as co-lead national coordinating counsel for AstraZeneca in thousands of product liability lawsuits alleging that its atypical antipsychotic drug, Seroquel, causes diabetes and related injuries. He was also regional counsel defending AstraZeneca against product liability cases alleging that its anesthetic, administered via a shoulder pain pump, caused chondrolysis (loss of cartilage). In addition, Arthur was part of the Kaye Scholer team that served as national trial counsel to Pfizer in Rezulin litigation.
Arthur is also an experienced commercial litigator. Currently, Arthur represents a large pharmaceutical manufacturer in an action brought by venture capitalists alleging securities and common law causes of action and is part of the team defending former members of AIG’s senior management in a complex fraud action brought by the New York Attorney General’s office under the Martin Act. In addition, he recently advised AstraZeneca in a breach of contract claim brought by Verus Pharmaceuticals stemming from an alleged breach of a Collaboration Agreement to develop a pediatric asthma treatment. The case was dismissed on pretrial motion and the dismissal was upheld on appeal. Arthur has also assisted and defended pharmaceutical companies in government and Congressional investigations related to marketed medicines.
Arthur’s group has been highly ranked by Chambers USA for the past few years. In Chambers USA 2014, clients noted that the group ‘“do[es] a terrific job when it comes to responsiveness and ha[s] really good client relationships.’” The Legal 500 USA 2013 ranks Kaye Scholer’s Product Liability group in Tier 1. Arthur was also a part of the Kaye Scholer team that was awarded Product Liability Firm of the Year at the 2008 Chambers and Partners “USA Awards for Excellence” ceremony.
Arthur has also been individually acknowledged for his impressive work, garnering recognition by Chambers USA 2014–2016 as a Leading Lawyer in Product Liability & Mass Torts. Arthur is described by clients as “‘smart, strategic, easy to work with and responsive.’” Arthur has also been recognized by The Best Lawyers in America 2016 for Product Liability Litigation, by Litigation and Product Liability Lawyers (2014) Expert Guide by Legal Media Group and was recommended by The Legal 500 United States 2013 for his work in Product Liability and Mass Tort Defense – Pharmaceuticals and Medical Devices. In 2012, 2013, 2014 and 2015, Arthur was named a “Life Science Star” in Euromoney’s LMG Life Sciences Guide.
From 1994 to 1997, Arthur served as an Assistant District Attorney in the New York County District Attorney’s office, where he prosecuted a wide range of cases involving street crime, conspiracy, fraud and embezzlement.
In The Market
- Ten Kaye Scholer Practices Recognized, 29 Individuals Cited in Legal 500 US 2016 June 15, 2016 • 评级与认同
- Kaye Scholer Practices and Attorneys Recognized by Chambers USA 2016 May 31, 2016 • 评级与认同
- Benchmark Litigation 2016 Honors Kaye Scholer with Antitrust and Product Liability Awards February 16, 2016 • 评级与认同